Pilot access
Explore a BactoAI pilot.
BactoAI is a research prototype, not approved for clinical use.
Research Access
For academic and public-health partners.
- Pilot pricing for LMICs
- Research and surveillance collaboration
- 3 antibiotics currently modeled, with more planned
Pilot
Seeking sites for planned independent validation; no clinical validation has been done yet.
- Supervised evaluation on local isolates
- Conventional laboratory confirmation
- Joint review of pilot outcomes
Partnership
Co-development and data collaboration.
- Collaborative model development
- Genomic data collaboration by agreement
- Shared research and validation goals
Current modeled scope: Meropenem, Ciprofloxacin, and Cefotaxime.
FAQ
Frequently asked questions
BactoAI is a research prototype that predicts antimicrobial resistance from assembled genomes in FASTA. It supports phenotypic susceptibility testing and does not replace it. Not approved for clinical use.
